Opko

The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.

The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.

GeneDx will provide whole-exome and whole-genome sequencing, among other services, to neonatal intensive care units staffed with Pediatrix-affiliated doctors.

In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity

LabCorp's test is being made available pursuant to FDA guidance that allows high-complexity, CLIA-certified labs to perform their own tests for SARS-CoV-2.

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The partners are planning to conduct meta-analyses of shared exome datasets from patients with inherited neurological disorders.

Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.